ChemML Discovery Platform
Accelerating drug discovery through chemistry machine learning and strategic collaborations.
Executive Summary
The ChemML Discovery Platform by Insitro is a cutting-edge machine learning platform specifically designed to accelerate drug discovery and development. It leverages advanced AI/ML techniques to analyze complex biological and chemical data, enabling the identification of novel therapeutic targets and the prediction of drug efficacy and safety. The platform is utilized in strategic collaborations with external partners, integrating diverse datasets such as diagnostic information for chronic disorders (neurodegenerative, ophthalmic, metabolic diseases), UK Biobank data (e.g., dual-energy X-ray for liver fat content), and histological images (H&E for molecular biomarker prediction). This multi-modal data integration allows for a comprehensive understanding of disease mechanisms and drug interactions. By applying machine learning to these rich datasets, the ChemML Discovery Platform aims to overcome traditional drug discovery challenges, such as identifying resistance mechanisms to therapies (e.g., TRK kinase inhibitors) and predicting digital biomarkers, ultimately streamlining the discovery process and bringing new treatments to patients faster.
Use Cases
- Predicting liver fat content using multi-modal data from biobanks like the UK Biobank.
- Predicting molecular biomarkers from histological images (e.g., H&E) for oncology research.
- Expanding research efforts in neurodegenerative, ophthalmic, and metabolic diseases using diagnostic data.
- Identifying and overcoming acquired resistance mechanisms to kinase inhibitors in cancer therapy.
- Discovering novel drug targets and mechanisms for various chronic disorders.
Features
Intelligence
- Predictive Biomarker Identification: Utilizes ML to predict molecular and digital biomarkers from diverse data sources like H&E images, diagnostic records, and biobank data.
- Disease Mechanism Elucidation: Applies ML to multi-modal data to understand underlying disease mechanisms across neurodegenerative, ophthalmic, and metabolic conditions.
- Drug Resistance Analysis: Identifies and analyzes mechanisms of acquired resistance to therapies, such as TRK kinase inhibitors, to inform new drug development strategies.
- Multi-Modal Data Integration: Integrates and analyzes various data types, including clinical diagnostics, genomic data, and imaging data (e.g., dual-energy X-ray, H&E), for comprehensive insights.
Technical Specifications
AI/ML Stack
- Machine Learning
Pricing
- Starting Price
- Contact sales
- Target Customer
- Enterprise,Research Institutions,Pharmaceutical Companies
About Insitro
Insitro is a machine learning-enabled drug discovery and development company that integrates multimodal data from human cohorts and cellular models with the power of AI and machine learning. The company aims to uncover genetic targets and new therapeutic hypotheses to accelerate the discovery and development of novel medicines.